Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15.
Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Lukšić I, Nair H, McAllister DA, Campbell H, Rudan I, Black R, Knoll MD. · 2018
Read Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. by Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Lukšić I, Nair H, McAllister DA, Campbell H, Rudan I, Black R, Knoll MD. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6005122.txt.
Introduction
Wahl and co-authors estimate the child disease burden from pneumococcus and Hib in the conjugate vaccine era. Their study appeared in The Lancet Global Health. Both vaccines are now used in most countries. The team built global, regional, and national estimates. They combined mortality and illness data with cause shares. Vaccine trial effects set the shares for each pathogen. HIV rates, care access, and vaccine use were factored in.
In 2015, pneumococcus caused an estimated 294,000 deaths, they report. Hib caused about 29,500 deaths in uninfected children. Pneumococcal deaths fell by half since 2000. Hib deaths fell by 90 percent over that span.
Catalog record
| CREATOR | Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Lukšić I, Nair H, McAllister DA, Campbell H, Rudan I, Black R, Knoll MD. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15 By Brian Wahl, Katherine L O'Brien, Adena Greenbaum, Anwesha Majumder, Li Liu, Yue Chu, Ivana Lukšić, Harish Nair, David A McAllister, Harry Campbell, Igor Rudan, Robert Black Published in: The Lancet. Global Health DOI: 10.1016/S2214-109X(18)30247-X ABSTRACT Summary Background Pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine are now used in most countries. To monitor global and regional progress towards improving child health and to inform national policies for disease prevention and treatment, we prepared global, regional, and national disease burden estimates for these pathogens in children from 2000 to 2015. Methods Using WHO and Maternal and Child Epidemiology Estimation collaboration country-specific estimates of pneumonia and meningitis mortality and pneumonia morbidity from 2000 to 2015, we applied pneumococcal and Hib cause-specific proportions to estimate pathogen-specific deaths and cases. Summary estimates of the proportion of pneumonia deaths and cases attributable to these pathogens were derived from four Hib vaccine and six PCV efficacy and effectiveness study values. The proportion of meningitis deaths due to each pathogen was derived from bacterial meningitis aetiology and adjusted pathogen-specific meningitis case–fatality data. Pneumococcal and Hib meningitis cases were inferred from modelled pathogen-specific meningitis deaths and literature-derived case–fatality estimates. Cases of pneumococcal and Hib syndromes other than pneumonia and meningitis were estimated using the ratio of pathogen-specific non-pneumonia, non-meningitis cases to pathogen-specific meningitis cases from the literature. We accounted for annual HIV infection prevalence, access to care, and vaccine use. Findings We estimated that there were 294 000 pneumococcal deaths (uncertainty range [UR] 192 000–366 000) and 29 500 Hib deaths (18 400–40 700) in HIV-uninfected children aged 1–59 months in 2015. An additional 23 300 deaths (15 300–28 700) associated with pneumococcus and fewer than 1000 deaths associated Hib were estimated to have occurred in children infected with HIV. We estimate that pneumococcal deaths declined by 51% (7–74) and Hib deaths by 90% (78–96) from 2000 to 2015. Most children who died of pneumococcus (81%) and Hib (76%) presented with pneumonia. Less conservative assumptions result in pneumococcccal death estimates that could be as high as 515 000 deaths (302 000–609 000) in 2015. Approximately 50% of all pneumococcal deaths in 2015 occurred in four countries in Africa and Asia: India (68 700 deaths, UR 44 600–86 100), Nigeria (49 000 deaths, 32 400–59 000), the Democratic Republic of the Congo (14 500 deaths, 9300–18 700), and Pakistan (14 400 deaths, 9700–17 000]). India (15 600 deaths, 9800–21 500), Nigeria (3600 deaths, 2200–5100), China (3400 deaths, 2300–4600), and South Sudan (1000 deaths, 600–1400) had the greatest number of Hib deaths in 2015. We estimated 3·7 million episodes (UR 2·7 million–4·3 million) of severe pneumococcus and 340 000 episodes (196 000–669 000) of severe Hib globally in children in 2015. Interpretation The widespread use of Hib vaccine and the recent introduction of PCV in countries with high child mortality is associated with reductions in Hib and pneumococcal cases and deaths. Uncertainties in the burden of pneumococcal disease are largely driven by the fraction of pneumonia deaths attributable to pneumococcus. Progress towards further reducing the global burden of Hib and pneumococcal disease burden will depend on the efforts of a few large countries in Africa and Asia. Funding Bill & Melinda Gates Foundation. INTRODUCTION Streptococcus pneumoniae (pneumococcus) and Haemophilus influenzae type b (Hib) are common causes of pneumonia, meningitis, and other serious infections in children. Pneumococcus was estimated to be responsible for 735 000 deaths in HIV-uninfected children and 14·5 million total illnesses in children in 2000.1 Hib was estimated to have caused 363 000 deaths in HIV-uninfected children and 8·1 million total episodes in children in the same year.2 These estimates represent the most recent, publicly available WHO national-level disease burden measures for these pathogens. Updated regional mortality estimates were published by WHO for 2008, estimating 541 000 pneumococcal deaths and 203 000 Hib deaths that year.3 Research in contextEvidence before this studyWe previously conducted a systematic review of invasive disease caused by Streptococcus pneumoniae (pneumococcus) and Haemophilus influenzae type b (Hib). On the basis of this review and using data from other sources, pneumococcus was estimated to be responsible for 735 000 deaths and Hib for 363 000 deaths in HIV-uninfected children in 2000. Updated estimates later published online for the year 2008 estimated that pneumococcus accounted for 541 000 deaths and Hib accounted for 203 000 deaths that year. The Institute for Health Metrics and Evaluation estimated that pneumococcus was responsible for 393 000 pneumonia deaths and Hib for 59 000 pneumonia deaths in children younger than 5 years in 2015.Added value of this studyWe present updated national estimates of pneumococcal and Hib mortality and morbidity due to all syndromes associated with these pathogens (ie, pneumonia, meningitis, and other invasive diseases) from 2000 to 2015. These estimates incorporate new data from 67 studies published between 2006 and 2014 that report on pathogen-specific meningitis case fatality and the distribution of meningitis cases by aetiology. Methods for estimating pneumococcal and Hib meningitis morbidity and mortality have been updated. To account for substantial within-country disease risk disparities, we developed India subnational pathogen-specific disease burden models for all syndromes associated with these pathogens for the first time.Implications of all the available evidenceTo our knowledge, the results presented here are the most up-to-date estimates available of pneumococcal and Hib mortality and morbidity attributable to all syndromes. These estimates highlight global progress towards reducing the morbidity and mortality associated with these two pathogens and indicate countries and regions where intensified prevention and treatment efforts are needed. They can be used to inform national child health intervention strategies. Several important vaccine developments have occurred since 2000. Protein-polysaccharide conjugate Hib vaccines are now included in the routine immunisation schedule of almost every country worldwide. By the end of 2015, 129 countries, including 54 low-income and middle-income countries eligible for vaccine funding support from Gavi, the Vaccine Alliance, had introduced pneumococcal conjugate vaccine (PCV); this number increased to 141 countries by September, 2017.4 Where Hib vaccine is used routinely with high coverage, virtual elimination of invasive Hib disease in children has occurred.5, 6, 7 Similarly, PCV has substantially reduced vaccine-type invasive pneumococcal disease among children.8, 9, 10 To measure progress towards reducing the burden of pneumococcal and Hib disease and inform the introduction and sustained use of prevention and treatment policies in the era of conjugate vaccines, we prepared annual modelled country-specific estimates of pneumococcal and Hib morbidity and mortality from 2000 to 2015 in children aged 1–59 months using country-specific data inputs whenever possible. METHODS Conceptual models and inputs We estimated annual pneumococcal and Hib deaths, cases, mortality rates, and incidence rates for each country from 2000 to 2015 for each of the three primary syndromes associated with these pathogens: pneumonia, meningitis, and invasive non-pneumonia, non-meningitis (NPNM). We developed conceptual models for each syndrome (figure 1). For the pneumonia models, we identified PCV and Hib vaccine trials and effectiveness studies from a systematic review of the literature (see appendix pp 4–8 for search strategy) and a Cochrane review of PCV efficacy.11 We also updated a systematic